COMP <GO>
APMD vs WVE // RSI-14 & 200D SMA MOMENTUM
Apnimed Inc. (NASDAQ) VS. Wave Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: APMD 1
— WVE 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: WVE
LAST: $17.34 (-9.45%) • MKT CAP: $721.9M
rsi-technicals
35.3
LAST: $3.63 (-0.28%) • MKT CAP: $715.9M
rsi-technicals
49.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APMD VS. WVE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APMD | WVE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -60.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.85 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 35.3 | 49.1 | -13.75 | WVE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $721.9M | $715.9M | $5.9M | APMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APMD REV | WVE REV | APMD GROSS % | WVE GROSS % | APMD FCF | WVE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $42.7M | — | — | — | -$188.2M |
| FY 2024 | — | $108.3M | — | — | — | -$152.0M |
| FY 2023 | — | $113.3M | — | — | — | -$19.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APMD // BETA —
WVE // BETA —